Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR+ breast cancer patients undergoing CDK4/6 treatment

Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR+ breast cancer patients undergoing CDK4/6 treatment

Despite improved clinical outcomes, intrinsic or acquired resistance to CDK4/6 inhibitor treatment has limited the success of this treatment in HR+HER2− metastatic breast cancer patients. Biomarkers are urgently needed, and longitudinal biomarker measurements may harbor more dynamic predictive and p...

Full description

Bibliographic Details
Main Authors: Nadia Dandachi, Florian Posch, Ricarda Graf, Christoph Suppan, Eva Valentina Klocker, Hannah Deborah Müller, Jörg Lindenmann, Angelika Terbuch, Ellen Heitzer, Marija Balic
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Molecular Oncology
Subjects:
CDK4/6 therapy
circulating tumor DNA
joint model
longitudinal biomarker analysis
metastatic breast cancer
Online Access:https://doi.org/10.1002/1878-0261.12870

Internet

https://doi.org/10.1002/1878-0261.12870

Similar Items